Lamotrigine Pharmacokinetics, Safety, and Drug Interactions
This session reviews Lamotrigine Pharmacokinetics, Safety, and Drug Interactions and its most clinically relevant points for exam preparation and bedside decision-making.
Duration
00:00:38
File size
0.31 MB
Practitioner-Guided Note
For Lamotrigine Pharmacokinetics, Safety, and Drug Interactions, use the highest-yield facts to drive concrete treatment decisions. Pay particular attention to Half-life: 24h monotherapy, ~12h with enzyme inducers (carbamazepine/phenobarbital), ~60h with valproate, ~60% protein-bound; extensively hepatically metabolized, and ~10% develop rash; risk higher in children and with valproate when choosing therapy, counseling about risk, planning monitoring, and deciding when closer follow-up or escalation is needed.
Key Takeaways
Half-life: 24h monotherapy, ~12h with enzyme inducers (carbamazepine/phenobarbital), ~60h with valproate~60% protein-bound; extensively hepatically metabolized~10% develop rash; risk higher in children and with valproateSaturable phenytoin metabolism >12-15 mcg/mL causes disproportionate level increasesEnzyme induction impairs warfarin-phenytoin interaction